Safety, efficacy and prognostic analyses of sunitinib in the post-marketing surveillance study of Japanese patients with gastrointestinal stromal tumor.

MLA

Yoshito Komatsu, et al. “Safety, Efficacy and Prognostic Analyses of Sunitinib in the Post-Marketing Surveillance Study of Japanese Patients with Gastrointestinal Stromal Tumor.” Japanese Journal of Clinical Oncology, vol. 45, no. 11, Nov. 2015, pp. 1016–22. EBSCOhost, https://doi.org/10.1093/jjco/hyv126.

APA

Yoshito Komatsu, Emiko Ohki, Naomi Ueno, Ai Yoshida, Yasuharu Toyoshima, Eiji Ueda, Hiroyuki Houzawa, Kanae Togo, & Toshirou Nishida. (2015). Safety, efficacy and prognostic analyses of sunitinib in the post-marketing surveillance study of Japanese patients with gastrointestinal stromal tumor. Japanese Journal of Clinical Oncology, 45(11), 1016–1022. https://doi.org/10.1093/jjco/hyv126

Chicago

Yoshito Komatsu, Emiko Ohki, Naomi Ueno, Ai Yoshida, Yasuharu Toyoshima, Eiji Ueda, Hiroyuki Houzawa, Kanae Togo, and Toshirou Nishida. 2015. “Safety, Efficacy and Prognostic Analyses of Sunitinib in the Post-Marketing Surveillance Study of Japanese Patients with Gastrointestinal Stromal Tumor.” Japanese Journal of Clinical Oncology 45 (11): 1016–22. doi:10.1093/jjco/hyv126.